These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2326777)

  • 21. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation.
    McBane RD; Wysokinski WE; Chesebro JH; Owen WG
    Thromb Haemost; 1995 Sep; 74(3):879-85. PubMed ID: 8571315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
    Callas DD; Fareed J
    Thromb Res; 1996 Sep; 83(6):463-8. PubMed ID: 8885140
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity.
    Sugidachi A; Asai F; Koike H
    Thromb Res; 1993 Jan; 69(1):71-80. PubMed ID: 8465276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
    Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
    Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic effects of hirulog in a rat carotid endarterectomy model.
    Jackson MR; Reid TJ; Tang DB; O'Donnell SD; Gomez ER; Alving BM
    J Surg Res; 1996 Jan; 60(1):15-22. PubMed ID: 8592407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs.
    Abendschein DR; Recchia D; Meng YY; Oltrona L; Wickline SA; Eisenberg PR
    J Am Coll Cardiol; 1996 Dec; 28(7):1849-55. PubMed ID: 8962575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides.
    Klauser RJ; Raake W; Meinetsberger E; Zeiller P
    J Pharmacol Exp Ther; 1991 Oct; 259(1):8-14. PubMed ID: 1656031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of recombinant hirudins in the management of thrombotic disorders.
    Fischer KG
    BioDrugs; 2004; 18(4):235-68. PubMed ID: 15244501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hirudin in renal insufficiency.
    Fischer KG
    Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonists of activated factor X and thrombin: innovative antithrombotic agents.
    Franchini M; Lippi G
    Curr Vasc Pharmacol; 2007 Apr; 5(2):121-8. PubMed ID: 17430216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
    Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
    Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of antithrombotic drugs.
    Thiagarajan P; Wu KK
    Adv Pharmacol; 1999; 46():297-324. PubMed ID: 10332506
    [No Abstract]   [Full Text] [Related]  

  • 39. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticoagulant, fibrinolytic and antithrombotic effects of the heparin-insulin complex].
    Liapina LA; Pastorova VE
    Izv Akad Nauk Ser Biol; 2002; (6):710-3. PubMed ID: 12561334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.